Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States
Tel: 650-587-5766
Fax: n./a
Website: http://www.protagonist-inc.com/
Email: info@protagonist-inc.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
JOBS:
Please click here for Protagonist Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
233 articles about Protagonist Therapeutics, Inc.
-
Protagonist Therapeutics Receives $1.45 Million SBIR Funding for the Development of PTG-300
9/6/2018
Grant supports translational research for hepcidin mimetic PTG-300 for potential treatment of rare blood disorders
-
Protagonist Therapeutics Expands Intellectual Property Portfolio
9/6/2018
Three issued U.S. patents add to existing protection for clinical drug candidates derived from Protagonist's innovative peptide technology platform
-
Protagonist Therapeutics Reports Granting of Inducement Award to Niall Murphy
8/17/2018
Protagonist Therapeutics, Inc. reported that on August 15, 2018, it issued an inducement award to Niall Murphy, the Company's recently hired Vice President, Corporate Controller, in accordance with the terms of Mr. Murphy's employment offer letter.
-
Protagonist Therapeutics Reports Second Quarter 2018 Financial Results
8/7/2018
Protagonist Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2018.
-
Protagonist Therapeutics Secures $22 Million Equity Financing
8/6/2018
The transaction is expected to close on Aug. 8, 2018.
-
Final Results from the Protagonist PROPEL Study Support Further Clinical Development of PTG-100 for the Treatment of Ulcerative Colitis
8/6/2018
Independent blinded re-read of endoscopies provides signal of clinical efficacy and identifies human error in initial reads provided by contract research organization
-
Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting
6/18/2018
Protagonist Therapeutics, Inc. announced that results of a Phase 1 study in healthy volunteers and supportive pre-clinical data for the Company's novel injectable hepcidin mimetic
-
Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference
6/6/2018
Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the 2018 JMP Securities Life Sciences Conference
-
Protagonist Therapeutics Reports Granting of Inducement Award
6/1/2018
The award was granted under the Protagonist Therapeutics Inducement Award Plan, which was adopted May 29, 2018.
-
On May 19 every year the people who are afflicted with IBD disorders unite across the globe to raise awareness of the disease and urge governments and healthcare systems to continue to focus on the development of necessary treatments.
-
Protagonist Therapeutics Appoints Bryan Giraudo to Board of Directors
5/16/2018
Protagonist Therapeutics, Inc. (Nasdaq: PTGX) today announced the appointment of Bryan Giraudo to its Board of Directors. Mr. Giraudo currently serves as Chief Financial Officer of Gossamer Bio and was previously Senior Managing Director at Leerink Partners.
-
Protagonist Therapeutics Announces Oral Presentation Accepted for Digestive Diseases Week Conference
5/3/2018
Protagonist Therapeutics, Inc. announced that preclinical research findings on the Company's selective dual mu/delta opioid receptor agonists have been accepted for oral presentation on Saturday, June 2, 2018 at the Digestive Diseases Week® (DDW) conference.
-
Protagonist Therapeutics Discontinues Phase 2b PROPEL Trial of PTG-100 for the Treatment of Ulcerative Colitis following Interim Analysis
3/26/2018
Protagonist Therapeutics, Inc. announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).
-
Shares of Protagonist Therapeutics plunged more than 60 percent in pre-market trading after the company announced it will discontinue its Phase IIb ulcerative colitis treatment after a review from an Independent Data Monitoring Committee (DMC).
-
Protagonist Therapeutics Reports Fourth Quarter and Year-End 2017 Financial Results
3/7/2018
Protagonist Therapeutics, Inc. reported its financial results for the fourth quarter and full year ended December 31, 2017 and provided an update on the company's recent achievements.
-
FDA Grants Orphan Drug Designation for Protagonist Therapeutics' PTG-300 for the Treatment of Beta-Thalassemia
3/6/2018
Protagonist Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for PTG-300, the company's sub-cutaneous injectable hepcidin mimetic for the treatment of beta-thalassemia.
-
Protagonist Therapeutics Granted Two New U.S. Patents for Peptide Drug Candidates PTG-100 and PTG-300
1/4/2018
The new patent adds to previously granted U.S. patents No. 9,273,093 and 9,518,091, which also provide protection for the company's alpha-4-beta-7 integrin peptide inhibitors, including PTG-100.
-
Protagonist Therapeutics Announces Final Phase I Study Results With Novel Hepcidin Mimetic, PTG-300
12/14/2017
PTG-300 treatment was well-tolerated, with no serious adverse events or dose-limiting toxicities reported.
-
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
12/14/2017
Protagonist Therapeutics today announced the appointment of Sarah Noonberg, M.D., Ph.D., CMO of Prothena, to the Protagonist Board of Directors.
-
Protagonist Therapeutics Initiates Phase I Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200
11/9/2017
The novel drug candidate enters development as potential 'oral targeted therapy' for inflammatory bowel disease.